drugset / Trial / NCT02798367

Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia

NCT02798367

Phase 2/3 Unknown 307 enrolled Ache Laboratorios Farmaceuticos S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

National clinical trials, phase II/III, combined in two stages, randomized, double-blind, controlled, parallel, study of superiority, in which three hundred and seven (307) participants of both sexes, aged equal or more than 55 years will be randomly allocated to one of three treatment groups. In the first stage. The group 01 will use Melatonin 3mg plus CBT-I, the group 02 will use Melatonin 5mg plus CBT-I and the group 03 will use CBT-I plus placebo. Based on the results of an interim analysis will be making a decision on whether to proceed with the study and, if so, on which the doses will be selected for the second stage of the study, to be better studied. The final analysis of the treatments, melatonin in the selected dose plus CBT-I versus CBT-I alone and placebo, will include participants from both stages.

Timeline

Start
2018-03-22
Primary completion
2021-10-31
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 3 mg Oral
Subject Melatonin Small molecule 5 mg Oral

Indications